EP1501523A4 - Carbon monoxide as a biomarker and therapeutic agent - Google Patents
Carbon monoxide as a biomarker and therapeutic agentInfo
- Publication number
- EP1501523A4 EP1501523A4 EP02807413A EP02807413A EP1501523A4 EP 1501523 A4 EP1501523 A4 EP 1501523A4 EP 02807413 A EP02807413 A EP 02807413A EP 02807413 A EP02807413 A EP 02807413A EP 1501523 A4 EP1501523 A4 EP 1501523A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- biomarker
- therapeutic agent
- carbon monoxide
- monoxide
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2002/014836 WO2003094932A1 (en) | 2002-05-09 | 2002-05-09 | Carbon monoxide as a biomarker and therapeutic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1501523A1 EP1501523A1 (en) | 2005-02-02 |
EP1501523A4 true EP1501523A4 (en) | 2006-12-13 |
Family
ID=29418043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02807413A Withdrawn EP1501523A4 (en) | 2002-05-09 | 2002-05-09 | Carbon monoxide as a biomarker and therapeutic agent |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1501523A4 (en) |
JP (1) | JP2005532314A (en) |
KR (1) | KR20040106515A (en) |
CN (1) | CN1638781A (en) |
AU (1) | AU2002308676B2 (en) |
BR (1) | BR0215717A (en) |
CA (1) | CA2484770A1 (en) |
EA (1) | EA200401478A1 (en) |
MX (1) | MXPA04011113A (en) |
NO (1) | NO20044865L (en) |
RS (1) | RS96904A (en) |
UA (1) | UA84402C2 (en) |
WO (1) | WO2003094932A1 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
US7011854B2 (en) | 2002-02-04 | 2006-03-14 | Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda | Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
CA2481972A1 (en) | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating ileus |
CA2481786A1 (en) | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
ATE521357T1 (en) * | 2002-05-17 | 2011-09-15 | Univ Yale | METHOD FOR TREATING HEPATITIS |
JP2005345242A (en) * | 2004-06-02 | 2005-12-15 | Tohoku Univ | Evaluation method of chemotherapy medical treatment effect of lung cancer |
JPWO2007073005A1 (en) * | 2005-12-22 | 2009-06-04 | 学校法人慶應義塾 | Methyl group transfer regulator |
EP2099439A2 (en) * | 2006-12-06 | 2009-09-16 | Alfama - Investigação E Desenvolvimento De Produto | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
JP2010094122A (en) | 2008-06-12 | 2010-04-30 | Keio Gijuku | Diagnosis-treatment option for head-and-neck tumor using micro-rna as biomarker |
JP2012046470A (en) * | 2010-08-30 | 2012-03-08 | Japan Science & Technology Agency | Enzyme activity inhibitor for gapdh |
CA2824056C (en) * | 2011-01-14 | 2019-01-08 | Children's Hospital Los Angeles | Solution of carbon monoxide for treatment of disease, including sickle cell disease |
US8927750B2 (en) | 2011-02-04 | 2015-01-06 | Universitaet Zu Koeln | Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules |
US9359197B2 (en) | 2011-03-24 | 2016-06-07 | Technion Research & Development Foundation Ltd. | Method of diagnosing, prognosing and monitoring parkinson's disease |
EP2699242B1 (en) | 2011-04-19 | 2017-11-01 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
WO2013013179A1 (en) | 2011-07-21 | 2013-01-24 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
US10031126B2 (en) | 2013-04-04 | 2018-07-24 | The Regents Of The University Of California | System and method for utilizing exhaled breath for monitoring inflammatory states |
EP2868348A1 (en) * | 2013-11-04 | 2015-05-06 | Universität Zürich | CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair |
TW201618795A (en) * | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | Systems and methods to improve organ function and organ transplant longevity |
JP7161737B2 (en) * | 2017-01-30 | 2022-10-27 | 哲也 石川 | Methods for testing malignant tumors |
EP3804731A4 (en) * | 2018-06-08 | 2022-04-06 | Sumitomo Seika Chemicals Co., Ltd. | Composition for skin wounds |
CN112236150A (en) | 2018-06-08 | 2021-01-15 | 住友精化株式会社 | Composition for inflammatory digestive organ diseases |
US20220296636A1 (en) * | 2019-06-06 | 2022-09-22 | The General Hospital Corporation | Carbon Monoxide as a Treatment for Neurodegenerative Disease |
US20230346831A1 (en) * | 2020-07-16 | 2023-11-02 | Cornell University | Methods for treating metastatic cancer using low dose carbon monoxide |
US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882674A (en) * | 1994-06-18 | 1999-03-16 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic system comprising active substances representing carbon monoxide sources |
WO2002078684A2 (en) * | 2001-03-30 | 2002-10-10 | Sangstat Medical Corporation | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5293875A (en) * | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
EP0921807B1 (en) * | 1996-08-27 | 2003-11-05 | Messer Griesheim GmbH | Hydrogenous medicament |
-
2002
- 2002-05-09 UA UA20041210106A patent/UA84402C2/en unknown
- 2002-05-09 EA EA200401478A patent/EA200401478A1/en unknown
- 2002-05-09 CA CA002484770A patent/CA2484770A1/en not_active Abandoned
- 2002-05-09 JP JP2004503016A patent/JP2005532314A/en active Pending
- 2002-05-09 BR BR0215717-9A patent/BR0215717A/en not_active Application Discontinuation
- 2002-05-09 KR KR10-2004-7018082A patent/KR20040106515A/en not_active Application Discontinuation
- 2002-05-09 EP EP02807413A patent/EP1501523A4/en not_active Withdrawn
- 2002-05-09 AU AU2002308676A patent/AU2002308676B2/en not_active Ceased
- 2002-05-09 CN CNA028292995A patent/CN1638781A/en active Pending
- 2002-05-09 RS YUP-969/04A patent/RS96904A/en unknown
- 2002-05-09 WO PCT/US2002/014836 patent/WO2003094932A1/en active Application Filing
- 2002-05-09 MX MXPA04011113A patent/MXPA04011113A/en active IP Right Grant
-
2004
- 2004-11-09 NO NO20044865A patent/NO20044865L/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882674A (en) * | 1994-06-18 | 1999-03-16 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic system comprising active substances representing carbon monoxide sources |
WO2002078684A2 (en) * | 2001-03-30 | 2002-10-10 | Sangstat Medical Corporation | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
Non-Patent Citations (9)
Title |
---|
L.E. OTTERBEIN: "Carbon monoxide: innovative anti-inflammatory properties of an age-old gas molecule", ANTIOXIDANTS AND REDOX SIGNALING, vol. 4, no. 2, April 2002 (2002-04-01), pages 309 - 319, XP009068341 * |
LEFER D J ET AL: "A comparison of vascular biological actions of carbon-monoxide and nitric-oxide", SCISEARCH, 1993, XP002960667 * |
OTTERBEIN L E ET AL: "Carbon monoxide provides protection against hyperoxic lung injury", AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 276, 1999, pages L688 - L694, XP002960664, ISSN: 1040-0605 * |
See also references of WO03094932A1 * |
SHAHIN ET AL.: "Carboxyhemoglobin in pediatric sepsis and the systemic inflammatory response syndrome", CLINICAL INTENSIVE CARE, vol. 11, no. 6, 2000, pages 311 - 317, XP009072820 * |
THIEMERMANN C.: "Inhaled CO: deadly gas or novel therapeutic?", NATURE MEDICINE, vol. 7, no. 5, 2001, pages 534 - 535, XP002401894 * |
VASSALLI F ET AL: "Inhibition of hypoxic pulmonary vasoconstriction by carbon monoxide in dogs", DRUGU, 1999, XP002960668 * |
YUAN S ET AL: "Evidence of increased endogenous carbon monoxide production in newborn rat endotoxicosis", BIOSIS, 1998, XP002960665 * |
ZEGDI ET AL.: "Increased endogenous CO prodution in severe sepsis", INTENSIVE CARE MEDICINE, vol. 23, 10 April 2002 (2002-04-10), pages 793 - 796, XP002401895 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002308676A1 (en) | 2003-11-11 |
JP2005532314A (en) | 2005-10-27 |
NO20044865L (en) | 2004-12-07 |
UA84402C2 (en) | 2008-10-27 |
BR0215717A (en) | 2005-02-22 |
CN1638781A (en) | 2005-07-13 |
RS96904A (en) | 2007-02-05 |
KR20040106515A (en) | 2004-12-17 |
WO2003094932A1 (en) | 2003-11-20 |
EA200401478A1 (en) | 2005-12-29 |
MXPA04011113A (en) | 2005-02-14 |
EP1501523A1 (en) | 2005-02-02 |
AU2002308676B2 (en) | 2009-06-11 |
CA2484770A1 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1501523A4 (en) | Carbon monoxide as a biomarker and therapeutic agent | |
EG23566A (en) | Use of oxyhydroxide compounds for reducing carbon monoxide in the mainstram smoke of a cigarette | |
EP1671584A4 (en) | Lancing unit and lancing apparatus | |
GB0310922D0 (en) | Bed | |
AU2003297908A8 (en) | Articulated elements and methods for use | |
AU2003233738A8 (en) | Oxygen reduction catalyst | |
AU2003302013A8 (en) | Therapeutic delivery of carbon monoxide | |
GB0228074D0 (en) | Carbon dioxide absorption | |
GB2413963B (en) | Improved airway device | |
GB0219660D0 (en) | Therapeutic use | |
PL397022A1 (en) | Therapeutic agent | |
GB0200941D0 (en) | Laryngoscopes and parts thereof | |
GB0217391D0 (en) | Improvements in activated carbon | |
GB2402890B (en) | Systems and methods for carbon monoxide clean-up | |
GB2385331B (en) | Modified carbon black | |
AU2003303654A8 (en) | Carbon nanotubes | |
AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
EP1569928A4 (en) | Therapeutic compounds and methods | |
ZA200409035B (en) | Carbon monoxide as a biomarker and therapeutic agent | |
GB0409376D0 (en) | Therapeutic delivery of carbon monoxide | |
GB0228048D0 (en) | Track set | |
EP1736544A4 (en) | Gm1 PROMOTER AND USE THEREOF | |
GB2386099B (en) | Support and dedicated pen assembly | |
GB2401786B (en) | Portable baptistry | |
GB0228391D0 (en) | Carbon monoxide shut off protection device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: OTTERBEIN, LEO, E. Inventor name: CHOI, AUGUSTINE, M., K. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1072179 Country of ref document: HK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 19/02 20060101ALI20060630BHEP Ipc: A61P 25/28 20060101ALI20060630BHEP Ipc: A61P 17/02 20060101ALI20060630BHEP Ipc: A61P 11/00 20060101ALI20060630BHEP Ipc: A61K 33/00 20060101AFI20031126BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20061109 |
|
17Q | First examination report despatched |
Effective date: 20070404 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: CARBON MONOXIDE FOR USE TO TREAT LOCALIZED INFLAMMATION OF KIDNEY |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120322 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1072179 Country of ref document: HK |